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ABSTRACT
Poor postnatal growth after preterm birth does not match the normal rapid growth in utero
and is associated with preterm morbidities. Insulin-like growth factor 1 (IGF-1) axis is the
major hormonal mediator of growth in utero, and levels of IGF-1 are often very low after
preterm birth. We reviewed the role of IGF-1 in foetal development and the corresponding
preterm perinatal period to highlight the potential clinical importance of IGF-1 deficiency in
preterm morbidities.
Conclusion: There is a rationale for clinical trials to evaluate the potential benefits of IGF-1
replacement in very preterm infants.
INTRODUCTION
Insulin-like growth factor 1 (IGF-1) is a 70-amino acid
single peptide mitogenic hormone, similar in structure to
proinsulin, which stimulates systemic body growth in
many different species. IGF-1 is produced in most organs,
but the liver is the main source of circulating IGF-1 (1–3).
The IGF-1/insulin axis is central to the control of
metabolism, promoting growth and cell survival for almost
every cell and organ in the body. Both insulin and IGF-1
promote cellular uptake of glucose. Insulin, which has
mainly metabolic functions, primarily targets organs that
are involved in storing energy and are mediated by
activation of the insulin receptor, such as adipose tissue,
muscle and the liver. IGF-1, which predominantly medi-
ates growth and differentiation, initiates intracellular
signalling through multiple pathways by binding to its
specific tyrosine kinase receptor, the IGF-1 receptor (4).
The IGF-1 receptor is present in many cell types in many
tissues (5), including nerve and brain cells, vascular
endothelial cells, skeletal muscle, lungs, cartilage, bones,
liver, kidneys, skin and hematopoietic cells (6–8). Approx-
imately 98% of IGF-1 is bound to one of the seven binding
proteins Insulin-like growth factor binding proteins
Abbreviations
BPD, Bronchopulmonary dysplasia; IGF-1, Insulin-like growth
factor 1; IGFBP, Insulin-like growth factor binding proteins;
MRI, Magnetic resonance imaging; ROP, Retinopathy of prema-
turity; VEGF, Vascular endothelial growth factor.
Key notes
 Poor postnatal growth after preterm birth does not
match the normal rapid growth in utero and is associ-
ated with preterm morbidities.
 We reviewed the role of insulin-like growth factor (IGF-
1) in foetal development and the corresponding
preterm perinatal period to highlight its potential
clinical importance in preterm morbidities.
 There is a rationale for clinical trials to evaluate the
potential benefits of IGF-1 replacement in very preterm
infants.
576 ©2016 The Authors. Acta Pædiatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Pædiatrica 2016 105, pp. 576–586
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Acta Pædiatrica ISSN 0803-5253
(IGFBP). IGFBP-3, which is the most common, accounts
for 80% of the IGFBP bound IGF-1. In the circulation,
IGF-1/IGFBP-3 may be bound into a ternary complex
with an acid labile subunit (9).
In the perinatal period, the levels of IGF-I and IGFBP-3
are low and the levels of IGFBP-1 are high, compared to
older children and adults (10). At the same time, the acid
labile subunit is often undetectable in foetal serum at
27 weeks of gestation (11). One of the acid labile subunit’s
main roles is the extension of IGF-1 half-life by protecting it
from degradation and preventing the passage of IGF-1 to
the extravascular compartment. Hence, binding to proteins
in the perinatal period is different than in older children
and adults, as is IGF-1 availability.
IGF-1 FUNCTION
Insulin-like growth factor 1 plays a key role in maintaining
homoeostasis, increasing progenitor cell potential and
improving physiologic performance under both rest and
stress conditions and is a potent inhibitor of programmed
cell death (12,13). In addition, IGF-1 has insulin-like effects
and is involved in glucose and lipid metabolism (14). In the
foetus, IGF-1 and insulin, which promotes IGF-1 produc-
tion (14), rather than growth hormone is the main driver of
growth (15). IGF-1-dependent growth is mediated by the
glucose–insulin axis, which allows a rapid response to
nutritional fluctuations (16), and concentrations of IGF-1
normally rise throughout mid–late gestation to support the
accelerated growth that normally occurs in the third
trimester in utero (8,16,17).
IGF-1 mechanism of action
Insulin-like growth factor 1 regulates cell differentiation
and proliferation through modulation of cellular DNA
synthesis (12) and is one of the most potent natural
activators of the protein kinase B (PKB or Akt) signalling
pathway, which stimulates cell proliferation. A key IGF-1
pathway is regulated by phosphatidylinositol-3 kinase
(PI3K) and its downstream partner, the mammalian target
of rapamycin (mTOR), which upregulates Akt driving
growth. IGF-1 also binds to the insulin receptor at lower
affinity than to the IGF-1 receptor, to activate the insulin
receptor at approximately 0.01 times the potency of insulin.
Part of this signalling may be via IGF-1 receptor/insulin
receptor heterodimers (14).
IGF-1 is a major growth hormone in the foetus
There is abundant genetic and experimental evidence
suggesting that the IGF-1 system is a very important
endocrine determinant of foetal growth (18). Although
IGF-2 has some effect on foetal and placental development
(19–21), direct measurements of IGF-1 and IGF-2 support
the predominant role of IGF-1 in foetal growth. Human
foetal serum IGF-1 concentrations in utero from 15 to
37 weeks of gestational age correlate with foetal weight and
bone length (20–23).
Umbilical cord IGF-1 concentrations reflect foetal IGF-1
levels at birth and correlate with birth weight. Cord serum
IGF-1 concentrations are lower at preterm birth and
following intrauterine growth restriction. In contrast,
serum IGF-2 concentrations do not correlate with foetal
length (22,24). IGF-1 is also detectable in many foetal
tissues from the first trimester (25,26), suggesting that IGF-
1 even plays a role in early foetal development. However,
the increase in circulating IGF-1 during the period of foetal
life that corresponds to the third trimester, suggests that
IGF-1 is more important in the later months of foetal
growth (Fig. 1).
Figure 1 Mean foetal blood IGF-1 concentrations (samples obtained by cordocentesis from normal pregnancies measured by RIA) double from 18 to 42 weeks of
gestational age (GA) (n = 174) (213, 257). This figure combines data from Lasarre et al. and Bang et al. on IGF1 levels in utero.
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ORGAN-SPECIFIC ROLES OF IGF-1 IN THE FOETUS
Animal studies of IGF-1 in growth and metabolism
Extensive evidence for the growth promoting effects of IGF-
1 in utero comes from mice, with selected deletions of IGF-
1 and the IGF-1 receptor. IGF-1 and IGF-1 receptor null
mice are severely growth restricted (40–65%) (27,28) and
die shortly after birth due to respiratory failure from lack of
lung and diaphragmatic muscle development. They also
have generalised organ hypoplasia, including the skin,
bones and brain, and exhibit neurologic deficits (28).
Manipulation of IGF-1 production in various tissues
indicates endocrine as well as autocrine/paracrine IGF-1
effects on growth (29,30). Laboratory studies show that
IGF-1 promotes glucose uptake in peripheral tissues
(31,32). This was demonstrated in a liver-specific IGF-1
deficient mouse model, which showed a 75% reduction in
circulating IGF-1 with insulin insensitivity in muscle.
Treatment of these animals with IGF-1 reduced hyperinsu-
linemia and improved insulin sensitivity, providing evi-
dence for IGF-1 as an important component of overall
insulin action in peripheral tissues (33).
Human genetic studies of IGF-1 and growth in utero
In humans, genetic defects of IGF-1 and IGF-1 receptor are
rarely seen in viable infants, but four case reports of
polymorphisms of the IGF-1 gene in patients have
described intrauterine growth restriction or being born
small for gestational age as well as microcephaly, sen-
sorineural deficits, developmental delay and metabolic
abnormalities (34,35). The severity of the foetal growth
restriction is illustrated with birth weight standard deviation
scores (SDS) ranging from 2.5 to 3.5 (Table 1) (36–40).
Evaluating growth hormone genetic defects also helps
our understanding of the critical role of IGF-1 versus
growth hormone in foetal growth. In the full-term infant,
postnatal production of IGF-1 is predominantly growth
hormone dependent, but this is not the case in utero.
Children with growth hormone deficiency or growth hor-
mone insensitivity are normal size at birth. However, after
birth, growth hormone axis defects lead to IGF-1 deficiency
and growth restriction. Children who are born preterm do
not respond with increased growth-to-growth hormone in
the perinatal period (8,15).
IGF-1/insulin regulation in the foetus and newborn
During foetal life, serum IGF-1 concentration is regulated
by the nutrient supply from the mother and the foetus is
continuously supplied with a diet rich in carbohydrates and
amino acids and low in fat (41,42).
Energy is mainly produced by glycolysis, and the capacity
to generate energy through more efficient oxidative phos-
phorylation of fat is poor. In the foetus, fatty acids are
stored mainly in liver and adipose tissue instead (43).
Immediately after birth, a brief period of starvation occurs
before milk, which is high in fat and low in carbohydrates, is
ingested.
The regulation of the growth hormone/IGF-1/insulin
axis in the foetus and the newborn infant is very different to
that observed during childhood and adult life (Fig. 2A, B).
In childhood, although hepatic IGF-1 generation is
driven by the growth hormone, insulin has a permissive
role at the hepatic growth hormone receptor. Insulin also
regulates hepatic production of IGFBP-1, which is an
inhibitor of IGF bioactivity. When nutrition is poor,
reduced levels of portal insulin will lead to impaired IGF-
1 production and increased levels of IGFBP-1. However, in
the preterm newborn infant, hepatic IGF-1 generation is
not controlled by the growth hormone and nutrition and
insulin play more important roles. The acid labile subunit
levels are reduced, and this means that much of the
circulating IGF-1 is in binary complexes. Insulin through
IGFBP-1 plays an important role in regulating IGF-1
bioactivity. Finally, there is evidence that in the newborn
infant, IGF-1, signalling through the IGF1 receptor, may
have a role in maintaining pancreatic beta cell function
(44).
The adult pattern of growth hormone regulation of
hepatic IGF-1 production is not present in the foetus and
only emerges gradually in the term newborn infant, reflect-
ing the appearance of growth hormone-binding protein in
Table 1 SDS scores of birth weight, length, head circumference and presence of microcephaly, developmental delay and adiposity in patients with various homozygous IGF-1
defects (36–39)
Woods et al. (37) Bonapace et al. (38) Walenkamp et al. (39) Netchine et al. (36)
Birth weight SDS 3.9 4.0 2.5 2.5
Birth length SDS 5.4 6.5 3.0 3.7
Birth head circ. SDS 4.9 7.5 2.5
Microcephaly Yes Yes Yes
Developmental delay Yes* Yes† Yes‡ Yes§
Adiposity No Increased abdominal
Fat mass No
*Moderately delayed motor development and behavioural difficulties, with hyperactivity and a short attention span.
†Delayed psychomotor development and poor responses to sound were noted.
‡Severe mental retardation (IQ <40) and motor unrest.
§Wechsler Intelligence Scale for Children III testing showed a 70–75 development quotient.
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the circulation. Full growth hormone regulation of IGF-1
production is not established until the second year of
postnatal life. The role of growth hormone in the foetus and
newborn infant is not completely characterised and levels
may be high in the preterm infant. Growth hormone may
regulate metabolism through its effects on lipolysis and
ketogenesis. It has been suggested that when growth
hormone acts through nonhepatic growth hormone recep-
tors, with or without tissue specific IGF-1 generation, it may
play a role in the early development of the brain, pancreas
and other organs.
Insulin is the primary regulator of hepatic IGF-1 gener-
ation in the foetus and the newborn infant, and through
insulin, it is augmented by the direct and indirect effects of
nutrients, such as glucose and protein.
As well as regulating hepatic IGF-1 production, insulin
inversely regulates the hepatic production of IGFBP-1,
which in turn inhibits IGF-1 bioactivity. Low levels of
insulin are associated with reduced hepatic IGF-1 genera-
tion and increased levels of IGFBP-1, leading to reduced
IGF-1 bioactivity. Free IGF-1 levels and IGF-1 bioavail-
ability are thought to be critical to the development of
pancreatic beta cell mass and subsequent insulin secretion
in newborn infants. Islet cell-specific IGF receptor knock-
outs develop insulin deficiency within the first few days of
postnatal life. In humans, birth is followed by a period of
beta cell apoptosis, which is thought to be induced by
reductions in placental IGF-2. This is followed by re-
establishment of beta cell insulin secretion linked to
nutritional and gut peptide (GLP-1) secretion. The complex
interactions between insulin and IGF-1 are critical to
understanding subsequent IGF-1-linked preterm complica-
tions (45–48).
IGF-1 and adipose tissue in the foetus
Adipose tissue, which is a complex and highly active
metabolic endocrine organ, is a target for both IGF-1 and
insulin. It responds to signals from hormones and the
central nervous system and secretes growth factors and
adipokines, such as leptin and adiponectin, with important
endocrine functions (49). Dysfunctional adipose tissue that
has too much or too little fat mass has been associated with
insulin insensitivity and type 2 diabetes (50,51). At
24 weeks of gestational age, a foetus contains very little
fat (52) and the third trimester is a period of intense
adipogenesis, involving proliferation and mitotic expansion
of committed pre-adipocytes. This is followed by terminal
differentiation, which leads to activation of lipid and
carbohydrate metabolism genes.
Mature adipocytes contain a single large lipid droplet. In
a study of preterm infants, the lipid content of white adipose
tissue increased from 184 to 547 mg/g adipose tissue, which
was consistent with a larger proportion of pre-adipocytes in
less mature infants (53). In vitro human pre-adipocytes
contain half as much insulin receptor as IGF-1 receptor
protein, while in mature adipocytes, 10 times more insulin
receptor than IGF-1 receptor protein is found. Thus,
adipocyte differentiation is characterised by an increased
insulin receptor/IGF-1 receptor ratio, which indicates that
insulin sensitivity increases with increasing gestational age
(54). In keeping with this, foetal tissues are thought to be
less responsive to insulin until 28–30 weeks of gestation
(55). Thus, it appears that IGF-1-dependent proliferation
and the differentiation of pre-adipocytes must take place
before insulin-dependent storage of fat can proceed.
IGF-1 and foetal brain development
The developing brain requires very large amounts of energy
and animal studies provide evidence that endogenous brain
IGF-1 serves to augment brain glucose utilisation during
development (56). In contrast, insulin does not seem to be
involved in the regulation of brain metabolism (57). As well
as increasing brain glucose uptake and energy metabolism,
in vivo and in vitro studies show that IGF-1 is important for
normal growth and development of the central nervous
system (58). IGF-1 influences brain cell proliferation,
Figure 2 (A) Describes the relationship between insulin and the GH/IGF-1 axis
in childhood and in (B) preterm newborn. GH, growth hormone; GHBP, growth
hormone-binding protein; GH receptor, growth hormone receptor; BP1, IGF
binding protein 1; IGF-1, insulin growth factor 1, BPs, IGF binding proteins, ALS,
acid labile subunit, IGFR, IGF-1 receptor.
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apoptosis, myelination, neurogenesis, maturation and dif-
ferentiation (58,59,S61). IGF-1 losses in genetic experi-
ments involving mice affected all aspects of brain
development, resulting in a 35% reduction in brain volume
(S61). In contrast, mice overexpressing IGF-1 had a 9–55%
increase in brain volume, reflecting an increase in cell size
and cell number in most brain areas (S62,S63).
All the reported IGF-1 gene defects in viable humans
have been associated with microcephaly and developmental
delay (36,40,S64–66) (Table 1). There is improved general
growth with IGF-1 treatment, including brain growth,
which is reflected in increased head circumferences in
children with growth hormone insensitivity syndrome (S67,
S68). The anti-apoptotic and neuronal and white matter
rescue effects of exogenous IGF-1 in the immature brain
have been evaluated after defined insults such as hypoxia–
ischaemia and induced inflammation in animal models
(S69). The effects of supplementary treatment with IGF-1
on long-term brain development in an animal model
mimicking very preterm birth have not yet been determined.
IGF-1 and foetal lung development
In mice, IGF-1 has been shown to be critical during
prenatal lung growth and organogenesis (S70–72). The cells
responsible for the local synthesis of IGF-1 in the lung are
type II pneumocytes, alveolar macrophages and mesenchy-
mal cells (S73,S74). Recent studies have shown that IGF-1
mRNA expression in the lung occurs predominantly during
foetal life and decreases before birth, becoming barely
detectable in the neonatal lung. Prenatal IGF-1 mutant
mice have thickened mesenchyme, alterations in cellular
matrix deposition, thinner smooth muscles and dilated
blood vessels. The addition of IGF-1 to embryonic IGF-1
deficient lungs cultured ex vivo increases airway septa
remodelling and distal epithelium maturation (S70). Mice
with a homozygous null mutation of the IGF-1 gene have
atelectatic lungs and high postnatal mortality due to lung
collapse and respiratory failure (28,S75,S76).
IGF-1 and foetal cardiovascular system development
The evidence for IGF-1 control of neonatal vascular growth
mostly comes from studies of vascular development in the
eye. IGF-1 is a critical nonoxygen-regulated factor in retinal
neurovascular development (S77–79). A lack of IGF-1 in
knockout mice prevented normal retinal vascular growth,
despite the presence of vascular endothelial growth factor
(VEGF), which is important to vessel development (S80)
(Fig. 3). Low in vitro levels of IGF-1/IGF receptor binding
prevent VEGF-induced activation of protein kinase B (Akt)
and mitogen-activated protein kinase, which are critical for
endothelial cell proliferation and survival (S80).
Cell culture and explant studies have shown that VEGF-
A and IGF-1 differ in their ability to stabilise newly formed
blood vessels and endothelial cell tubes. On its own, VEGF-
A fails to support an enduring vascular response. In
contrast to VEGF, IGF-1 stabilises newly developing blood
vessels, a function that is dependent on Erk activity and
associated with prolonged Erk activation (S81). There are
very few studies that provide genetic evidence for the role
of growth hormone and IGF-1 in foetal retinal vasculari-
sation in humans. However, one clinical report notes that
when there were defects in the growth hormone/IGF-1
axis, there was significantly less retinal vascularisation,
demonstrated by a lower number of vascular branching
points than in the reference group of 100 normal controls
(S82).
In vitro studies of foetal rat cardiomyocytes have shown
that IGF-1 inhibits apoptotic signalling of cardiomyocytes
(S83). It has also been shown that IGF-I treatment of foetal
lambs in late gestation was associated with increased
myocyte volume in male but not female lambs (S84).
LOSS OF IGF-1 AFTER PRETERM BIRTH
After very preterm birth, there is a precipitous decline in
serum IGF-1 concentrations (Fig. 4), which are on average
10 ng/mL compared to the average of >50 ng/mL mea-
A B
Figure 3 Effect of IGF-I inhibition on vascular growth. Mice were perfused with fluorescein dextran at postnatal day 5, eyes were enucleated, and retinas were examined
in flat mount. There was significantly retarded vascular growth (perfused vessels seen as bright green) in the retinas of the IGF-I/ mice (A) compared with littermate
IGF-I+/+ controls with normal IGF-I levels (B). The distance from the optic nerve to the vessel front (red arrow) vs optic nerve to periphery (yellow arrow) was
58  4.8% for IGF-I/ retinas vs 70.3  5.8% for IGF-I+/+ controls (p < 0.001), indicating that IGF-I is critical for normal vascular development and that low IGF-I in
the neonatal period could cause retardation of vascular growth. Figure by Hellstr€om et al., with permission from PNAS (S80).
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sured in utero at a postmenstrual age of 23–30 weeks
(23,60,S85,S86).
At IGF-1 levels of 10 ng/mL, VEGF signalling is
impaired (S86–88). The concentration of IGF-1 remains
very low after preterm birth, resulting in an increasing
disparity over time between IGF-1 serum concentrations in
preterm infants and the corresponding in utero levels. This
fall in IGF-1 levels is likely to be multifactorial, including
the impact of altered nutrient availability, insulin action,
hypoxia and inflammatory cytokines (S86,S89).
Factors influencing IGF-1 concentrations in preterm
infants
In adults and children, the secretion of IGF-1 is generally
dependent on nutrient availability, thereby ensuring that
growth is appropriate for the nutrient supply (S90). In this
setting, IGF-1 appears to be a clinically useful indicator of
nutritional status (S91), with concentrations increasing
with protein intake independent of total caloric consump-
tion (S92,S93). However, in very preterm infants increases
in protein and nutrient intake are not associated with early
postnatal growth or with increases in IGF-1 concentration
before 30 weeks of postmenstrual age, indicating deficient
nutrient utilisation (S94). In addition to under-nutrition
and malnutrition, hypoxia (S89), inflammation (S86) and
genetic factors and other hormones, such as T4, cortisol
and sex steroids, influence plasma IGF-1 concentrations
(S95).
Deficient energy metabolism
Normally, the newborn infant rapidly develops the path-
ways for fatty acid oxidation in mitochondria in liver,
muscle, kidney cortex and brown adipose tissue (S96).
Preterm birth is associated with delayed postnatal activa-
tion of mitochondrial oxidative phosphorylation and
impaired switch from glycolytic to oxidative metabolism
(S97–99). Thus, the energy status of a preterm neonate is
not just dependent on energy intake, but to what extent,
nutrients can be assimilated and converted to energy.
Loss of IGF-1 supply
During the third trimester, the foetus swallows significant
amounts of amniotic fluid, which contains higher con-
centrations of IGF-1 than cord blood during gestation or
at delivery (S100). Human milk, especially colostrum, also
contains IGF-1, although IGF-1 levels drop by 80% by 3
days of age (S101). Although preterm infants may be
given trophic feeds of maternal milk/colostrum, the
volumes are usually very small and maternal expression
of colostrum may be difficult during the immediate
postnatal period. Therefore, the loss of IGF-1 sources in
amniotic fluid and colostrum/milk may contribute to
lower IGF-1 levels.
Critical illness
In foetuses as well as in older children, hypoxia reduces
circulating IGF-1 (S89,S102). Variations in oxygenation
with episodes of both hypoxia and hyperoxia are common
during the first weeks of life in preterm neonates (S103).
Preterm delivery may be precipitated by infection and
inflammatory markers in cord blood are associated with
reduced IGF-1 concentrations (S86). Acute and chronic
hypoxia and inflammation also increase IGFBP-1 concen-
tration, which inhibits IGF-1 actions. In addition, very
preterm infants are susceptible to infection, which in adults
decreases circulating IGF-1 concentrations (S104).
Figure 4 Normal intrauterine IGF-1 concentrations obtained from the umbilical cord with cordocentesis over 18–42 weeks of gestational age (GA) (black circles)
(n = 174) (23,60) compared to preterm infants of matched postmenstrual ages (red dots) (S86,S87).
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CLINICAL IMPACT OF LOW IGF-1 LEVELS ON THE PRETERM INFANT
Low IGF-1 levels and growth retardation
In the preterm infant, the early neonatal period is a critical
time for growth and early growth is associated with better
short-term and long-term outcomes (S105). Studies have
shown that despite improvements in nutrient delivery,
postnatal growth remains poor, particularly in the first
month of life of extremely preterm infants (S106). This
period is associated with low IGF-1 levels and this impaired
growth may not be entirely reversible, affecting adult body
composition and metabolic processes (S107–108). In pre-
term infants, IGF-1 concentrations are positively correlated
with birth weight, length, head circumference and ponderal
index, a measure of leanness (17,S109). In extremely
premature infants, there is also a relationship between
persistently low IGF-1 concentrations and slow physical
growth (16,S110–114).
As shown in Figure 5, preterm infants have extrauterine
growth retardation from birth until around 30–32 weeks of
postmenstrual age, when growth accelerates, according to
data from four studies of longitudinal postnatal weight SDS
of extremely preterm infants (S115–118).
Insulin-like growth factor 1 concentrations in preterm
infants correlate inversely with standard deviation scores
for postnatal weight loss during the growth retardation
phase of up to about 30 weeks of postmenstrual age and
positively with weight gain during the later catch-up phase
after 30 weeks of postmenstrual age (S94). IGF-1 concen-
tration is only positively associated with calorie intake
when IGF-1 concentrations are higher, with later catch-up
growth after 30 weeks of postmenstrual age (S94).
Early low IGF-1 concentrations are associated with later
development of obesity. When preterm children reach 5
years of age, they have normal bone mass but less lean mass
and increased fat mass compared to full-term controls
(S119). High early postnatal IGF-1 concentration positively
predicts lumbar spine bone mass. Even in moderate to late
preterm infants, with gestational ages of 32–36 weeks at
birth, postnatal IGF-1 concentrations correlate with early
accelerated postnatal growth (S114).
Low IGF-1 levels and complications of preterm birth
A prolonged duration of low serum IGF-1 in extremely
premature infants is strongly associated with increased risk
of multiple major neonatal morbidities, which have a
significant impact on long-term health (S79,S86–88). These
include bronchopulmonary dysplasia (BPD), retinopathy of
prematurity (ROP), poor brain development and gener-
alised growth retardation.
Low IGF-1 levels and impaired brain development in
preterm infants
Preterm infants are born in a critical period of brain
development (S120) with increases in brain volume and
complexity being most marked from 25 to 40 weeks of
gestation in utero (S121) (Fig. 6).
There is evidence linking low postnatal IGF-1 concen-
trations in preterm infants with poor brain development.
With the development of magnetic resonance imaging
(MRI) neuroimaging, the impact of preterm birth on the
brain can be seen.
Postnatal head circumference has been correlated to
serum IGF-1 concentrations during postnatal life in
preterm born infants (S122) (Fig. 7).
In addition, mean IGF-1 concentrations between birth
and a postmenstrual age of 35 weeks positively and signif-
icantly correlate with total brain volume, un-myelinated
white matter volume, grey matter volume and cerebellar
volume, as estimated by volumetric MRI in a cohort of 52
extremely preterm infants (S87). In this same cohort, a
slower rate of increase in IGF-1 concentrations during early
postnatal life correlated with an increased risk of subnormal
mental development (5) at the corrected age of 24 months,
evidenced by Mental Developmental Index scores of <85
(S123).
IGF-1 and pulmonary development in preterm infants
Preterm infants have incomplete lung development and in
extremely preterm infants inadequate postnatal lung matu-
ration combined with postnatal lung injury results in BPD.
BPD is a serious complication, affected infants may require
oxygen supplements for months to years and some have
persistent lung dysfunction throughout adulthood. Despite
advances in neonatal care, BPD continues to affect a
significant proportion (25–42%) of extremely premature
infants and is a major contributor to long-term respiratory
impairment and extended hospitalisation (S124–127). BPD
has been characterised by impaired alveolar or microvas-
cular development (S128–130). In addition, in extremely
premature neonates, lower postnatal IGF-1 concentrations
during the first weeks after birth have been correlated with
later development of BPD independent of gestational age
and birth weight standard deviation score (S131,S132).
Figure 5 Change in weight SDS with increasing postmenstrual age (PMA)
illustrating phases of growth retardation and catch-up in preterm infants
compared to undisturbed intrauterine growth (purple line) (S112). Data from
1942 infants born at GA 23–28 weeks from North America and Sweden.
Figure courtesy of Susanna Klevebro.
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Preclinical interventional studies in rodent model suggest
that restoring IGF-1 concentration may prevent or treat
BPD, as IGF-1 was shown to have beneficial effects on
inflammatory lung injury and developmental repair (S133).
The relationship between IGF-1 and nutritional intake
has been shown to differ in premature infants with and
without BPD (S134), consistent with increased calorie
needs in children with BPD (S135). In preterm infants
without BPD, IGF-1 correlated positively with protein
intake and caloric intake over the 3 days before sample
collection and with weight change over the previous week
(r = 0.46). In contrast, infants with BPD only showed a
significant correlation between IGF-1 and weight change
(S134) and none with IGF-1 and nutrient intake. Animal
studies have added additional insights. IGF-1-treatment in
chronically hypoxic rats resulted in more weight gain than
vehicle-treated rats. These results suggest that IGF-1 treat-
ment promotes anabolism under chronic hypoxic condi-
tions (S136).
IGF-1 and vascular development in the preterm infant:
risks of ROP and cardiovascular disease
At preterm birth, the vascular system is not fully developed.
The contribution of low IGF-1 levels to poor postnatal
vascular development in preterm babies is best documented
in the setting of early retinopathy and long-term risks of
cardiovascular disease.
Preterm birth has been associated with overall cardio-
vascular mortality and morbidity in young adulthood: a
nationwide Swedish study showed that individuals born
before 32 weeks of postmenstrual age had a nearly twofold
increased risk of cerebrovascular disease (S137,S138).
Other data are also consistent with low IGF-1 linked with
preterm birth affecting many vascular beds. For example,
low neonatal IGF-1/IGFBP-1 ratios and severe ROP have
been associated with higher blood pressure in 4-year-old
children born very preterm, suggesting that low early IGF-1
concentrations could predict future cardiovascular morbid-
ity (S139).
As previously noted, most evidence about vascular
development in association with IGF-1 comes from studies
of the eye because of the problems of ROP, a common
morbidity of prematurity that has been associated with
lifelong poor visual acuity and visual disorders, including
blindness (S140,S141). A review estimated that in 2010,
approximately 20 000 infants worldwide had become blind
or severely visually impaired from ROP, with a further
12 300 being visually impaired (S142). The retina of an
infant is incompletely vascularised at preterm birth. Post-
natal retinal vascular growth is then compromised by low
IGF-1 concentrations and low VEGF concentrations
Figure 7 HCSDS at PMA 31 weeks correlate significantly with mean serum IGF-
1 levels from birth to PMA 31 weeks among 58 preterm children, Figure by
L€ofqvist et al. with permission from Pediatrics (S122).
Figure 6 Developmental processes and growth in normal brain development during gestation and after birth. Figure by Lagercrantz with permission from Cambridge
University Press (S121).
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compared to those in utero. As a result, vascularisation is
delayed and the retina becomes hypoxic. Neovascularisa-
tion and blindness can ensue (S79,S80,S88,S143). Serum
IGF-1 concentrations and duration of low IGF-1 correlate
strongly with severity of ROP (S79,S80,S144,S145). An
interventional preclinical study of oxygen-induced
retinopathy found that mice who received IGF-1 treatment
developed less retinopathy (p = 0.00001), which supports
the possible role of supplemental IGF-1 in preventing ROP
(S146).
Altered glucose metabolism in the preterm infant
Although insulin is the primary regulator of glucose
metabolism, IGF-1 also influences glucose homoeostasis.
During foetal life, glucose is the major fuel substrate. In
foetal lambs, glucose availability largely determined foetal
IGF-1 secretion, supporting the hypothesis that IGF-1 is
involved in foetal glucose homoeostasis (S147,S148).
Following preterm birth, energy requirements increase
and nutrient intake is very often inadequate so energy
requirements are not met. In addition, glucose metabolism
is frequently deranged by low IGF-1 levels. Hyperglycaemia
during the first weeks of life is strongly associated with
morbidities such as ROP (S149), which is similar to diabetic
retinopathy in many respects. It has been hypothesised that
early insulin replacement in preterm infants could reduce
hyperglycaemia and promote anabolism by increasing IGF-
1 concentrations and that this could have beneficial impact
on morbidity, mortality and growth. Pilot data have
supported this hypothesis, with early insulin treatment in
the first week of life increasing IGF-1 concentrations to
improve longitudinal growth (S150). A substudy demon-
strated that early intervention with insulin was related to
increased IGF-1 concentrations at 28 days and that low
IGF-1 concentrations were associated with hyperglycaemia,
increased morbidity and reduced growth (S132). Children
born preterm, as opposed to full term, have aspects of
metabolic syndrome, including decreased insulin sensitivity
and altered adiposity (S151,S152). This is consistent with
animal studies that have shown the relationship between
low circulating IGF-1 and insulin insensitivity (33).
In the 1990s, it was first shown (S153,S154) that IGF-1
concentrations in preterm infants correlated with nutri-
tional status and adequacy of nutrient intake. The relation-
ship between nutrient intake and IGF-1 concentrations in
preterm infants was confirmed (S93,S94,S111), although
the association between dietary protein intake IGF-1
concentrations and long-term outcomes of preterm infants
need to be further explored (S108).
RATIONALE FOR IGF-1 REPLACEMENT STUDIES
IGF-1 deficiency is well documented in the preterm
population, especially in those with intrauterine growth
retardation or in those born small for gestational age (S94).
Animal genetic studies and human gene defects in the IGF-
1 system have illustrated the consequences of low levels of
IGF-1 on foetal development (27,36). There are long-term
pathological consequences of early IGF-1 deficits in the
preterm population that are difficult to reverse, such as
cardiovascular disease (S139) or poor brain development
(20). Thus, early replacement of IGF-1 has both short-term
and long-term potential benefits to many organ systems.
IGF-1 treatment studies to date
An important question in a population with inadequate
nutrition is whether IGF-1 treatment can improve nutrient
utilisation. Intravenous infusions of IGF-1 given to rats fed
a diet with 50% of the calories they needed were associated
with an increase in body weight, without a change in food
intake, indicating improved food utilisation. A lower rate of
urea excretion was also seen, and this was presumably due
to decreased protein breakdown. No hypoglycaemia was
observed (S155). IGF-1 treatment in burn patients in a
catabolic state with high metabolic needs caused increased
body weight and decreased protein breakdown (S156). In
addition, head injury patients in a catabolic state benefitted
from IGF-1 infusion and aggressive nutrition compared to
aggressive nutrition alone, with more than a doubling of the
number of patients with improvement of outcome from
poor to good (S157). In a dose-dependent manner, IGF-1
treatment after hypoxic ischaemic brain injury in adult rats
reduced neuronal loss by providing trophic support within
most cerebral structures (S158).
Some adverse effects have been associated with intermit-
tent subcutaneous IGF-1 treatment. Laron syndrome
patients and patients with short stature are given daily or
twice daily subcutaneous doses of IGF-1. In some patients,
hypoglycaemia has occurred, which has been associated
with injection site lipohypertrophy and tonsillar hypertro-
phy and headache (S159). None of these adverse effects
have been observed to date when providing short-term
replacements of IGF-1 in preterm infants to normal in utero
concentrations with continuous infusion (S160). An ongo-
ing phase II trial will determine the safety, feasibility and
potential benefit and risks of IGF-1 replacement with IGF-
1/IGFBP-3 in extremely premature infants.
CONCLUSION
Following preterm birth, serum IGF-1 concentrations fall
and remain low for weeks to months. This may result in the
suppression of development during this period, correspond-
ing to the third trimester of pregnancy, with a loss of IGF-1
action during the period of rapid rise in utero, which occurs
at a postmenstrual age of 22–40 weeks. There have been
many reports of correlations between low IGF-1 and
complications of prematurity. These complications resem-
bled many developmental abnormalities of growth seen
with IGF-1 gene defects in experimental animals and in
humans. These included abnormalities of general growth
and metabolic derangement, such as insulin insensitivity,
lung immaturity and retinal immaturity – leading to ROP –
and brain developmental abnormalities leading to deficits in
cognitive function. Results of animal and human studies
indicate that IGF-1 treatment has the potential to have an
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important effect on the nutrient assimilation, growth and
development of infants born preterm. Clinical trials are
required to determine the risks and benefits of IGF-1
replacement in very preterm infants.
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